Physician profile
Ju Tang
NPI 1447455357
$779.76
in general payments reported to CMS, 2019-2025
17 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $92.76 · 2021: $21.25 · 2022: $59.56 · 2023: $61.42 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $141.57 | 2019-2020 | |
| Sk Life Science, INC. | $126.29 | 2025 | |
| Acadia Pharmaceuticals INC | $122.38 | 2025 | Daybue |
| Ucb, INC. | $93.19 | 2019-2023 | Briviact |
| Csl Behring | $43.48 | 2019-2020 | |
| Biocodex, INC. | $33.22 | 2025 | |
| Otter Pharmaceuticals, LLC | $30.92 | 2025 | Sympazan |
| Livanova USA, INC. | $27.27 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $27.24 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.59 | 2022 | |
| Greenwich Biosciences, INC. | $22.08 | 2020 | |
| Allergan, INC. | $21.25 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.03 | 2023 | Zonisade, Eprontia, Fleqsuvy |
| Neurelis, INC. | $16.82 | 2023 | Valtoco |
| Biomarin Pharmaceutical INC. | $14.99 | 2025 | Brineura |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $14.12 | 2019 | |
| Travere Therapeutics, INC. | $3.32 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ju Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.